Fort Worth’s AyuVis Receives $2.1M NIH Grant for Clinical Trial of New-Gen Immunotherapies

by | May 17, 2023
The grant from the National Heart, Lung, and Blood Institute will fund a first-in-human Phase 1 clinical trial of a new generation of immunotherapies. This is the fourth NIH grant AyuVis has received since its founding in 2014, doubling total non-dilutive funding to $4.2 million. Co-Founder and CEO Dr. Suchismita Acharya calls the move to a human trial "a huge milestone for AyuVis."
Follow the Money: OxeFit Lands New Celebrity Backers, Dallas Biotech Raises $10M to Fight Cancer, Blockchain Investor Raises New Fund-of-Funds, and More
by | May 17, 2022
What companies are finding funding or having a big exit? From startup investments to grants and acquisitions, Dallas Innovates tracks what’s happening in North Texas money.
Fort Worth Immunotherapy Startup Gets $1.8M Grant Ahead of First Clinical Trials
by | May 12, 2022
AyuVis, an immunotherapy startup, is set to get a $1.8 million Small Business Innovation Research grant from the Eunice Kennedy Shriver National Institute of Child Health and Human Development. The funding will support the pre-clinical research of its drug candidate to treat the second-leading cause of death in premature babies.

Founder Suchismita Acharya calls the timing "perfect."
Fort Worth’s AyuVis Is One Step Closer to Protecting Pre-Term Babies from a Leading Cause of Death
by | Mar 31, 2022
Fort Worth-based AyuVis just received its second patent in three months for its immunotherapy treatments that protect pre-term babies from a debilitating chronic lung disease that affects many pre-term infants on ventilators.

The startup's lead drug candidate—AVR-48—is scheduled for clinical trials this summer.